
In a controlled test of 12 AI models across 33 physician-written clinical cases, a clearly labeled pharmaceutical ad raised the share of responses choosing the advertised drug from 35% to 47.6%.
Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.





